论文部分内容阅读
链球菌制剂OK-432在体内外均能诱导干扰素,加强杀伤性T细胞和自然杀伤细胞活性,促进抗体产生.对慢性肝炎HBeAg阳性患者的治疗,血浆中DNA-多聚酶活性下降,停药后无反跳现象发生,作者把117例HBeAg阳性慢性乙型肝炎患者分为两组,OK-432治疗组42例,自然病程组(对照组)75例.治疗组肌肉注射OK-432制剂,每周两次,首剂0.2KE(KE为制剂浓度单位,1KE相当于0.1mg干细胞),以后每周递增至0.5、1.0和2.0KE,根据患者症状,剂量可以增减.
Streptococcus OK-432 in vitro and in vivo can induce interferon, enhance the activity of killer T cells and natural killer cells, and promote antibody production for the treatment of chronic hepatitis B HBeAg-positive patients, plasma DNA polymerase activity decreased, after stopping 117 cases of HBeAg-positive chronic hepatitis B patients were divided into two groups: OK-432 treatment group (42 cases) and natural course group (control group), 75 cases. The treatment group received OK-432 intramuscular injection, Twice a week, the first dose of 0.2KE (KE concentration units, 1KE equivalent to 0.1mg stem cells), after every week increased to 0.5,1.0 and 2.0KE, according to the patient’s symptoms, the dose can increase and decrease.